Haleon announces annual update to EMTN programme

Published 07/05/2025, 19:04
Haleon announces annual update to EMTN programme

Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, declared today the annual update of its Euro Medium Term Note (EMTN) Programme. The company, known for brands like Advil and Centrum, confirmed that the listing particulars dated May 7, 2025, for its £10 billion EMTN Programme, have been published. This programme is guaranteed by Haleon and involves Haleon UK Capital plc and Haleon Netherlands Capital B.V.

The listing particulars are now available for public inspection and can be downloaded from the company’s website. The document provides essential information for investors and is part of Haleon’s routine financial disclosures. The update is a standard practice for such financial instruments, which are used by companies to raise capital in international markets.

Haleon, which operates in various health-related sectors including Oral Health, Pain Relief, and Vitamins, Minerals and Supplements (VMS), has a strong presence in the consumer health industry. The company’s commitment to "deliver better everyday health with humanity" is backed by a portfolio of well-established products that are trusted by consumers worldwide.

The EMTN Programme plays a significant role in Haleon’s capital structure and financial strategy. The programme allows the company to issue debt securities over time, providing flexibility in financing its operations and growth initiatives.

Investors and media looking for further information can reach out to Haleon’s investor relations and corporate media contacts provided in the press release statement. The company has made it clear that the information contained in the listing particulars is intended for residents of particular countries and must be used in accordance with the specified guidelines.

This announcement is based on a press release statement from Haleon plc and does not constitute financial advice or an endorsement of the company’s financial products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.